$0.59 Earnings Per Share Expected for Haemonetics Co. (HAE) This Quarter

Equities analysts expect Haemonetics Co. (NYSE:HAE) to announce earnings per share (EPS) of $0.59 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Haemonetics’ earnings, with estimates ranging from $0.57 to $0.62. Haemonetics posted earnings per share of $0.62 in the same quarter last year, which indicates a negative year over year growth rate of 4.8%. The firm is expected to issue its next earnings results on Tuesday, February 5th.

According to Zacks, analysts expect that Haemonetics will report full year earnings of $2.33 per share for the current financial year, with EPS estimates ranging from $2.30 to $2.37. For the next fiscal year, analysts forecast that the company will post earnings of $3.04 per share, with EPS estimates ranging from $2.61 to $3.40. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Haemonetics.

Haemonetics (NYSE:HAE) last posted its earnings results on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.02. Haemonetics had a net margin of 2.26% and a return on equity of 16.04%. The company had revenue of $241.58 million during the quarter, compared to analyst estimates of $233.44 million. During the same period in the prior year, the business posted $0.48 earnings per share. Haemonetics’s revenue for the quarter was up 7.2% on a year-over-year basis.

A number of equities analysts recently issued reports on HAE shares. TheStreet downgraded shares of Haemonetics from a “b” rating to a “c+” rating in a research note on Monday, August 20th. Barrington Research reissued a “buy” rating and issued a $127.00 price target on shares of Haemonetics in a research note on Friday, October 5th. Finally, Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price target for the company in a research note on Friday, October 12th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $113.20.

In other Haemonetics news, CFO William P. Mr. Burke sold 13,056 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $114.33, for a total transaction of $1,492,692.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Pedro P. Granadillo sold 12,322 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $114.50, for a total transaction of $1,410,869.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 62,653 shares of company stock valued at $6,973,391. 1.04% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Thrivent Financial for Lutherans increased its stake in shares of Haemonetics by 5.9% during the third quarter. Thrivent Financial for Lutherans now owns 12,591 shares of the medical instruments supplier’s stock valued at $1,443,000 after purchasing an additional 696 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Haemonetics by 2.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 33,558 shares of the medical instruments supplier’s stock valued at $3,009,000 after purchasing an additional 810 shares in the last quarter. Xact Kapitalforvaltning AB increased its stake in shares of Haemonetics by 14.7% during the third quarter. Xact Kapitalforvaltning AB now owns 8,595 shares of the medical instruments supplier’s stock valued at $985,000 after purchasing an additional 1,100 shares in the last quarter. GAM Holding AG increased its stake in shares of Haemonetics by 22.4% during the second quarter. GAM Holding AG now owns 6,343 shares of the medical instruments supplier’s stock valued at $569,000 after purchasing an additional 1,159 shares in the last quarter. Finally, Riverhead Capital Management LLC increased its stake in shares of Haemonetics by 27.8% during the third quarter. Riverhead Capital Management LLC now owns 5,971 shares of the medical instruments supplier’s stock valued at $684,000 after purchasing an additional 1,300 shares in the last quarter. 98.37% of the stock is owned by institutional investors and hedge funds.

HAE stock traded down $2.03 during trading on Monday, reaching $103.17. The company had a trading volume of 609,233 shares, compared to its average volume of 444,407. Haemonetics has a 52 week low of $56.23 and a 52 week high of $117.56. The company has a market cap of $5.44 billion, a P/E ratio of 55.17, a PEG ratio of 3.61 and a beta of 1.09. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.92 and a quick ratio of 2.06.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Story: Momentum Indicator: Relative Strength Index

Get a free copy of the Zacks research report on Haemonetics (HAE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply